ICYMI: FDA approves Pexidartinib (Turalio): A Drug for Rare Joint Tumor

According to the American Journal of Managed Care (AJMC), the US Food and Drug Administration (USFDA) has approved Pexidartinib (Turalio) drug as first targeted therapy to treat symptomatic Tenosynovial Giant…

Continue Reading ICYMI: FDA approves Pexidartinib (Turalio): A Drug for Rare Joint Tumor